Enhanced Alpha-Emitter Radiation Therapy with Controlled Radon Release and Real-Time Beta Radiation Supplement
Legal Citation
Summary of the Inventive Concept
A novel radiation therapy system that combines alpha-emitter radiation with controlled radon release and real-time beta radiation supplement, providing a more efficient and personalized treatment for cancer patients.
Background and Problem Solved
The original patent disclosed an interstitial source with combined alpha and non-alpha radiation for cancer treatment. However, it had limitations in controlling radon release and optimizing beta radiation. The new inventive concept addresses these limitations by introducing a controlled desorption probability of radon release and a real-time beta radiation supplement module, ensuring a more efficient and safe treatment.
Detailed Description of the Inventive Concept
The system comprises a radiation source with a controlled desorption probability of radon release, which is achieved through a specialized coating. The radiation source is paired with a beta radiation supplement module that can be adjusted in real-time to optimize the treatment. The system also includes a real-time radiation monitoring module to ensure safe and effective treatment. The radiation source can be personalized for individual patients based on their tumor characteristics, providing a more targeted treatment.
Novelty and Inventive Step
The new inventive concept introduces the controlled desorption probability of radon release, which is a significant improvement over the original patent. The real-time beta radiation supplement module and the personalization feature based on tumor characteristics are also novel and non-obvious aspects of the invention.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include different types of radiation sources, such as seeds or wires, and various methods for controlling radon release. The system could also be adapted for use in different types of cancer treatment, such as external beam radiation therapy.
Potential Commercial Applications and Market
The enhanced alpha-emitter radiation therapy system has significant commercial potential in the cancer treatment market, particularly in the area of personalized medicine. The system's ability to provide real-time monitoring and adjustment of beta radiation could lead to improved treatment outcomes and increased patient safety, making it an attractive option for hospitals and cancer treatment centers.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Radiation oncology and medical device design, specifically focused on targeted radiotherapy techniques for cancer treatment, requiring expertise in radioisotope engineering, radiation physics, and medical device development
Person of Ordinary Skill (PHOSITA) Profile
A medical physicist or biomedical engineer with advanced degrees, specialized knowledge in radiation therapy technologies, understanding of radionuclide decay processes, and experience designing targeted radiation delivery systems
Obviousness Rationale
A person having ordinary skill would recognize that the PTD represents a predictable extension of the source patent's core radiation therapy technology by introducing incremental improvements in radiation source design and delivery. The modifications represent standard engineering approaches to optimizing radiation therapy, including controlled release mechanisms and real-time monitoring. These variations would be considered routine problem-solving within the established technological framework of targeted radiation treatment.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,803 |
|---|---|
| Title | Diffusing alpha-emitter radiation therapy with enhanced beta treatment |
| Assignee(s) | Alpha Tau Medical Ltd |